Sellas Life Sciences Group Inc

AeroVironment rallied 30% in premarket trading after reporting earnings of $1.84 per share on revenue of $642 million, beating analyst estimates of $1.46 per share and $559 million. Digital Realty Trust sank 4.5% after agreeing to buy a stake in three data centers from Blackstone for $7.8 billion. Merck and AbbVie dipped slightly after Reuters reported a U.S. House committee probe into their involvement in China trials that may have aided military capabilities. Strategy lost more than 3%, giving back some of Monday's 22.6% surge, while Sellas Life Sciences added over 3% following a 24.7% jump on changes to executive severance agreements that could signal a potential takeover.

Universe Pharmaceuticals led biotech gainers Monday, soaring more than 300% after announcing a strategic acquisition to expand its pharmaceutical patent portfolio. The company agreed to acquire 100% of Best Praise International Limited, which holds five Chinese patents covering elderly healthcare, cognitive health, cardiovascular applications, antibacterial compounds, and drug delivery technologies, for US$10.75 million payable in 4,376,552 Class A ordinary shares. The deal is expected to close in the third quarter of 2026, and UPC closed at $12.18, up 311.49%. Other notable movers included Decoy Therapeutics, which jumped over 70% on a private placement financing of up to $21 million, and QuidelOrtho, up over 30% on reports it is exploring the sale of its point-of-care testing business for approximately $1.5 billion. SELLAS Life Sciences gained more than 24% as its Phase 3 REGAL trial of GPS in acute myeloid leukemia nears its final analysis, with 78 of the required 80 events reported as of May 11, 2026.

A bullish thesis on SELLAS Life Sciences Group, Inc. sees the stock as deeply undervalued with a potential upside of approximately 129.8% based on a post-data target price of $16.50 versus a current price around $7.18. The thesis centers on the Phase 3 REGAL study of galinpepimut-S in acute myeloid leukemia, where the trial has reached 78 of 80 required deaths as of May 2026, and the long duration is interpreted as a signal of strong survival benefit rather than delay risk. Final unblinding is expected after the last two events, potentially supporting regulatory submission by late 2026. The company is also advancing SLS009, a CDK9 inhibitor showing a 46% response rate in relapsed settings, and holds over $107 million in cash with a runway into 2028, limiting near-term dilution risk.

Sellas Life Sciences Group extended its winning streak to a sixth straight session on Thursday, climbing 14.83 percent to end at $10.53 apiece, following a regulatory filing that hinted at a potential acquisition. The company announced changes to employment and severance agreements for three executives—President and CEO Angelos Stergiou, Chief Finance Officer John Burns, and Chief Development Officer Dragan Cicic—under which they would receive lump sum payment benefits in the event of a change of control. Burns and Cicic are set to receive lump sum payments equal to 15 months of their base salary, target bonus for the year of termination, and immediate vesting of unvested shares, among other benefits, if terminated by new company owners. Investors interpreted the amendments as preparation for a potential takeover ahead of the looming results of the company's phase 3 clinical study of its therapy candidate for acute myeloid leukemia. Last month, Sellas said it would provide updates to the late-stage study as soon as it reaches the pre-determined 80th patient death, with data from that point deemed sufficient to analyze whether its Galinpepimut-S treatment candidate made a meaningful improvement over the placebo group; as of last month, the company had recorded 78 patient deaths.

Retail investors on social media are touting Sellas Life Sciences as a top biotech stock with huge upside potential. The company is developing a cancer immunotherapy drug called GPS, which trains a patient's immune system to attack cancer cells, and is currently testing it on acute myeloid leukemia in the REGAL trial. Bulls believe a successful trial readout would almost certainly trigger a buyout from a major pharmaceutical company, potentially making the drug a standard of care for leukemia and expanding to other cancers. Bears argue that a 10x return from the current price of around $8 to $9 is unrealistic, with most sober estimates pointing to a 3x to 5x return on a buyout. One social media commenter holding 168,000 shares and 2,500 deep-in-the-money call options described the stock as the strongest canon of due diligence they have ever found.